Wednesday, February 01, 2023 4:50:44 PM
CEO measuring stick isn't the share price.
nuff said...
Todos is a small company. Doesn't have Pfizer type money to buy crazy expensive AARP ads, SuperBowl Commercials or Blimp ads.
nuff said...
Many people predicted Todos couldn't' get Tollovir thought Phase II. Said it was all BS and would never happen. Guess what?
Not only did they, but the results were stellar.
nuff said...
Maybe people predicted Todos would never close the NCL Pharma deal. Guess what?
Todos closed the NCL Pharma deal. Not only that, but Dr. Dorit Arad, joined Todos Medical as the Chief Scientific Officer.
nuff said...
Maybe people predicted Todos wouldn't sell any Tollovid. Called it garbage. Called it fake. Guess what?
Todos selling millions of dollars of Tollovid all without an $800K ad in a magazine people throw out.
nuff said...
Super easy to focus on what a company hasn't done. Extremely easy. Some companies I follow haven't done squat ever. Not Todos. That's why I'm an investor. The risk vs reward are great at these levels for me as part of my portfolio
OINK
Recent TOMDF News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/17/2023 12:29:32 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM